Eric M. Dube, CEO of Travere Therapeutics ($TVTX), sold shares on the open market eight times over the past year, totaling about $10.9 million. His most recent sale occurred on February 20, 2026. These sales rank him 1,060th among 11,678 insiders by total value sold, above the average of $8.6 million across 6.4 transactions per insider. He made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 34902 | $30.55 | 457,984.0000 | 89,211,813 | 7.08% | 0.04% |
| April 1, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | M | Common Stock | 60000 | $15.46 | 492,886.0000 | 89,211,813 | 13.86% | 0.07% |
| April 1, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | M | Employee stock option (right to buy) | 60000 | $0.00 | 0.0000 | 89,211,813 | 100.00% | 0.07% |
| April 1, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 25098 | $31.46 | 432,886.0000 | 89,211,813 | 5.48% | 0.03% |
| Feb. 20, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | M | Common Stock | 60000 | $15.46 | 492,886.0000 | 89,211,813 | 13.86% | 0.07% |
| Feb. 20, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | M | Employee stock option (right to buy) | 60000 | $0.00 | 60,000.0000 | 89,211,813 | 50.00% | 0.07% |
| Feb. 20, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 60000 | $30.10 | 432,886.0000 | 89,211,813 | 12.17% | 0.07% |
| Feb. 3, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 66452 | $32.06 | 466,521.0000 | 89,211,813 | 12.47% | 0.07% |
| Jan. 31, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | A | Employee stock option (right to buy) | 303600 | $0.00 | 303,600.0000 | 89,211,813 | 9999.99% | 0.34% |
| Feb. 3, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 33635 | $32.70 | 432,886.0000 | 89,211,813 | 7.21% | 0.04% |
| Jan. 31, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | A | Common Stock | 113800 | $0.00 | 532,973.0000 | 89,211,813 | 27.15% | 0.13% |
| Jan. 23, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | M | Common Stock | 8135 | $15.46 | 427,308.0000 | 89,211,813 | 1.94% | 0.01% |
| Jan. 27, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | M | Employee stock option (right to buy) | 51865 | $0.00 | 120,000.0000 | 89,211,813 | 30.18% | 0.06% |
| Jan. 23, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | M | Employee stock option (right to buy) | 8135 | $0.00 | 171,865.0000 | 89,211,813 | 4.52% | 0.01% |
| Jan. 27, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 51865 | $30.10 | 419,173.0000 | 89,211,813 | 11.01% | 0.06% |
| Jan. 27, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | M | Common Stock | 51865 | $15.46 | 471,038.0000 | 89,211,813 | 12.37% | 0.06% |
| Jan. 23, 2026 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 8135 | $30.01 | 419,173.0000 | 89,211,813 | 1.90% | 0.01% |
| Oct. 28, 2025 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | M | Employee stock option (right to buy) | 92872 | $0.00 | 207,128.0000 | 102,618,560 | 30.96% | 0.09% |
| Oct. 28, 2025 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | M | Common Stock | 92872 | $15.46 | 512,045.0000 | 102,618,560 | 22.16% | 0.09% |
| Oct. 28, 2025 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 92872 | $30.38 | 419,173.0000 | 102,618,560 | 18.14% | 0.09% |
| Oct. 29, 2025 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | M | Common Stock | 27128 | $15.46 | 446,301.0000 | 102,618,560 | 6.47% | 0.03% |
| Oct. 29, 2025 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 27128 | $30.12 | 419,173.0000 | 102,618,560 | 6.08% | 0.03% |
| Oct. 29, 2025 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | M | Employee stock option (right to buy) | 27128 | $0.00 | 180,000.0000 | 102,618,560 | 13.10% | 0.03% |
| May 2, 2025 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | M | Performance-based restricted stock units | 18924 | $0.00 | 18,924.0000 | 78,888,861 | 50.00% | 0.02% |
| May 2, 2025 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | M | Common Stock | 18924 | $0.00 | 438,097.0000 | 78,888,861 | 4.51% | 0.02% |
| May 5, 2025 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 18924 | $21.05 | 419,173.0000 | 78,888,861 | 4.32% | 0.02% |
| Feb. 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 11375 | $24.04 | 419,173.0000 | 78,888,861 | 2.64% | 0.01% |
| Jan. 31, 2025 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | A | Employee stock option (right to buy) | 260000 | $0.00 | 260,000.0000 | 78,888,861 | 9999.99% | 0.33% |
| Jan. 31, 2025 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | A | Common Stock | 130000 | $0.00 | 481,239.0000 | 78,888,861 | 37.01% | 0.16% |
| Feb. 3, 2025 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 50691 | $20.21 | 430,548.0000 | 78,888,861 | 10.53% | 0.06% |
| Jan. 22, 2025 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 10736 | $19.46 | 351,239.0000 | 78,888,861 | 2.97% | 0.01% |
| Sept. 5, 2024 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | A | Common Stock | 32500 | $0.00 | 383,100.0000 | 74,267,418 | 9.27% | 0.04% |
| Sept. 9, 2024 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 21125 | $11.52 | 361,975.0000 | 74,267,418 | 5.51% | 0.03% |
| Jan. 31, 2024 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | A | Common Stock | 135000 | $0.00 | 369,722.0000 | 74,267,418 | 57.51% | 0.18% |
| Feb. 1, 2024 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 9106 | $8.53 | 360,616.0000 | 74,267,418 | 2.46% | 0.01% |
| Feb. 1, 2024 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 10016 | $8.86 | 350,600.0000 | 74,267,418 | 2.78% | 0.01% |
| Jan. 31, 2024 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | A | Employee stock option (right to buy) | 360000 | $0.00 | 360,000.0000 | 74,267,418 | 9999.99% | 0.48% |
| Jan. 23, 2024 | Travere Therapeutics, Inc. | $TVTX | Dube Eric M | CHIEF EXECUTIVE OFFICER | S | Common Stock | 7873 | $8.96 | 234,722.0000 | 74,267,418 | 3.25% | 0.01% |
| June 6, 2023 | OnKure Therapeutics, Inc. | $OKUR | Dube Eric M | Director | A | Stock Option (right to buy) | 17500 | $0.00 | 17,500.0000 | 0 | 9999.99% | 0.00% |